Brazilian multicenter study on pegvisomant treatment in acromegaly
Archives of Endocrinology and MetabolismObjective Investigate the therapeutic response of acromegaly patients to pegvisomant (PEGV) in a real-life, Brazilian multicenter study. Subjects and methods Characteristics of acromegaly patients treated with PEGV were reviewed at diagnosis, just ...
Cesar L. Boguszewski +14 more
doaj +1 more source
Epithelial sodium channel is a key mediator of growth hormone-induced sodium retention in acromegaly.: Antinatriuretic action of growth hormone [PDF]
, 2008 International audienceAcromegalic patients present with volume expansion and arterial hypertension, but the renal sites and molecular mechanisms of direct antinatriuretic action of GH remain unclear.
Blanchard, Anne +8 more
core +4 more sources
Non‐pituitary growth hormone enables colon cell senescence evasion
Aging Cell, Volume 23, Issue 8, August 2024.Growth hormone (GH), stimulated by DNA damage and CXCL1, is induced in senescent cells and is a component of senescence‐associated secretory phenotype (SASP). SASP GH triggers senescence evasion in a subset of senescence cells and activates epithelial‐to‐mesenchymal transition (EMT), resulting in post‐senescent cell migration and transformation ...
Vera Chesnokova +4 more
wiley +1 more source
AIP and MEN1 mutations and AIP immunohistochemistry in pituitary adenomas in a tertiary referral center. [PDF]
, 2019 Background: Pituitary adenomas have a high disease burden due to tumor growth/ invasion and disordered hormonal secretion. Germline mutations in genes such as MEN1 and AIP are associated with early onset of aggressive pituitary adenomas that can be ...
Cano González, David A. +2 more
core
Lanreotide extended-release aqueous-gel formulation, injected by patient, partner or healthcare provider in patients with acromegaly in the United States: 1-year data from the SODA registry [PDF]
, 2014 Lanreotide depot (LD; commercial name Somatuline® Depot) is an injectable, extended-release formulation of the synthetic somatostatin analog (SSA) lanreotide.
Gordon, Murray B. +4 more
core +1 more source
18F‐fluoro‐ethyl‐tyrosine PET co‐registered with MRI in patients with persisting acromegaly
Clinical Endocrinology, Volume 101, Issue 2, Page 142-152, August 2024.Abstract Objective To report our experience with 18F‐fluoro‐ethyl‐tyrosine (FET) positron emission tomography‐computed tomography (PET‐CT) co‐registered with magnetic resonance imaging (MRI) (FET‐PET/MRICR) in the care trajectory for persistent acromegaly. Design Prospective case series.
Leontine E. H. Bakker +13 more
wiley +1 more source
Guidelines on diagnostics and treatment of acromegaly (draft)
Ожирение и метаболизмWe recommend acromegaly to be ruled in all patients with characteristic changes in appearance (A3). In all patients without characteristic changes in appearance, we recommend to rule out acromegaly, if several clinical signs suspicious for acromegaly are
E. G. Przhiyalkovskaya +25 more
doaj +1 more source
Visceral Adiposity Index Is Associated with Insulin Sensitivity and Adipocytokine Levels in Newly Diagnosed Acromegalic Patients. [PDF]
, 2012 Context: The visceral adiposity index (VAI) has proved to be a marker of visceral adipose dysfunction, strongly associated with insulin sensitivity in both the general and specific populations of patients at metabolic risk. Objective: The objective of
AMATO, Marco Calogero +3 more
core +1 more source
Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly. [PDF]
, 2016 This work is licensed under a Creative Commons Attribution 3.0 Unported LicenseBACKGROUND: Long-acting somatostatin analogues delivered parenterally are the most widely used medical treatment in acromegaly.
Adelman +20 more
core +2 more sources